Fractional & Interim Operations
Fractional & Interim Operations Leadership for Life Sciences
Driving operational and value‑creation milestones at critical inflection points
- Mandates
- Fractional · Interim
- Focus
- Execution
- Reach
- Global
01 / What We Do
Operational delivery, not advisory analysis.
XPharm provides fractional and interim operations leadership to life sciences companies navigating complex transitions and execution risk. We work directly with boards, investors, and executive leadership teams when operational delivery is critical to enterprise value.
Our engagements are designed for situations where experience, authority, and speed matter more than advisory analysis.
02 / When to Engage
Common engagement triggers.
Clients typically engage XPharm when operational complexity, time pressure, or risk exposure exceeds internal capacity. Common engagement triggers include:
- 01Scaling global supply chains to support clinical progression or commercial readiness
- 02Operational instability following acquisition, divestment, or organisational restructuring
- 03Supplier risk, cost escalation, or failure of critical third‑party partners
- 04Trade, logistics, or regulatory exposure across multi‑jurisdictional operations
- 05Pre‑transaction or confirmatory operational due diligence
- 06Interim leadership gaps at COO or senior operations level
03 / How We Engage
Leadership roles, not consultancy.
XPharm operates exclusively in leadership roles, not as a traditional consultancy.
Engagement models include
- 01
Fractional COO / Operations Leader
Ongoing executive leadership (typically 1–2 days per week) focused on stabilisation, scale‑up, and delivery of defined milestones.
- 02
Interim COO / SVP Operations
Full‑time, fixed‑term executive mandates where immediate authority and accountability are required.
- 03
Board & Investor Operational Support
Targeted engagement during transactions, restructurings, or periods of heightened execution risk.
XPharm does not provide project management, staff augmentation, or functional consulting services.
04 / Areas of Accountability
Direct operational accountability.
XPharm typically assumes direct accountability across the following areas:
- 01
Global Supply Chain & Manufacturing
Design, stabilisation, and scale‑up of multi‑site, multi‑vendor supply chains supporting clinical and commercial programmes.
- 02
Supplier Selection, Escalation & Commercial Negotiation
Critical supplier selection, executive‑level escalation, and negotiation under time, cost, or performance pressure.
- 03
Trade Compliance & Cross‑Border Operations
Establishment and governance of compliant global trade, logistics, and import/export frameworks.
- 04
Global Operations Build‑Out
Design of operating models, organisational structures, and governance to support international expansion.
- 05
M&A Integration, Separation & Carve‑Outs
Operational integration, divestment planning, and execution following acquisitions or portfolio restructuring.
- 06
Operational Due Diligence
Assessment of operational risk, scalability, and execution readiness in pre‑ and post‑transaction contexts.
05 / Who We Work With
A small number of clients at any one time.
- 01
Private equity and venture capital investors
- 02
Biotech companies from clinical stage through commercial scale‑up
- 03
Pharmaceutical companies managing complex global operations
Engagements are limited to a small number of clients at any one time to ensure focus and delivery.
06 / Not the Right Fit
XPharm is deliberately selective.
We are not the right partner in the following situations:
- 01
You are looking for advisory recommendations rather than execution.
XPharm does not produce strategy decks or diagnostic reports without ownership of delivery.
- 02
You need functional specialists rather than senior leadership.
We do not act as clinical, regulatory, quality, or CMC subject‑matter experts, nor do we replace functional teams.
- 03
You are seeking long‑term organisational headcount.
XPharm is designed for time‑bound mandates. If the priority is a permanent executive hire, we may support the transition but are not a substitute for it.
- 04
The primary objective is cost reduction rather than risk management or value creation.
Our work is focused on preventing failure, delay, and mis‑execution at critical moments.
- 05
The organisation is not ready to delegate authority.
Successful engagements require executive‑level decision rights and accountability.
07 / About XPharm
XPharm was established to address a gap between advisory insight and executive accountability in life sciences operations.
We bring hands‑on leadership experience across supply chain, global operations, and transaction‑driven change, stepping in when outcomes—not recommendations—are required.
08 / Contact
Begin a confidential discussion.
For confidential discussion regarding fractional or interim engagement:
- Location
- Ireland · Global Mandates
- Connect